Phenobarbital Sodium

ApprovedSmall molecule

UUniversity of California, San Diego

Phenobarbital Sodium is one of 65 small molecule programs targeting Brain Injury. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain InjuryActive, not recruiting

Neonatal SeizureActive, not recruiting

Alcohol WithdrawalActive, not recruiting

Brain InjuryApproved

Active, not recruiting

Neonatal SeizurePreclinical

Active, not recruiting

Alcohol WithdrawalPreclinical

Active, not recruiting

Competition

Competitive Landscape

245 competitors in Brain Injury

#DrugCompanyPhaseTrials

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 2

Brintellix

Takeda

Phase 3

1 3

Zyloprim

Alnylam Pharmaceuticals

Phase 3

1 4

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

5 5

Cyklokapron

AAmring

Phase 3

4 6

Prometrium

Ferring

Phase 3

2 7

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

2 8

Nuvigil

NNuvo Research GmbH

Phase 3

2 9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

—10

Xe-133

NNobilis Therapeutics Inc.

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Neonatal Seizure

NCT05610085

Clinical

Trials by Indication[1]

Neonatal seizure4 trials

Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital.

Completed·HHayat Abad Medical Complex, Peshawar·N/A·NCT07401433·260 enrolled

Study to Evaluate Phenobarbital Sodium Injection for the Treatment of Neonatal Seizures

Withdrawn·PPharPoint Research, Inc.·Phase 3·NCT03602118

A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

Recruiting·UUniversity of California, San Diego·Phase 2·NCT05610085·133 enrolled

Show 1 more trial

Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures

Terminated·NNEMA Research, Inc.·Phase 3·NCT04320940·4 enrolled

Alcohol Withdrawal1 trial

Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome

Terminated·UUnity Health Toronto·N/A·NCT03586089·8 enrolled

Brain Injury1 trial

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT06081283·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Phenobarbital Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Phenobarbital Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Phenobarbital Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Diego company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of California, San Diego

Phenobarbital Sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Neonatal seizure4 trials

Alcohol Withdrawal1 trial

Brain Injury1 trial

References

Drug Info

Quick Facts

Related News